Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders-Reference-Cited by-同舟云学术

Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders

Published:2023-11 Issue: Volume:79 Page:104965
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Algu Priyanka,Hameed Natasha,DeAngelis Tracy,Stern Joel,Harel Asaff^ORCID

Funder

Biogen Inc

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference40 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

2. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat. Med.,2021

3. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients;Bajwa;Mult. Scler. Relat. Disord.,2022

4. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer;Bange;Nat. Med.,2021

5. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study;Bar-Or;Neurology,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination;Annals of Clinical and Translational Neurology;2024-05-07

2. Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination;2024-01-24

3. Post-vaccination SARS-Cov-2 T-cell receptor repertoires and multiple sclerosis and related disorders: Correspondence;Multiple Sclerosis and Related Disorders;2023-11